MiPortal
Blog post

What is Molecular Diagnostics? A Guide for Healthcare Professionals

13 August 2025
Molecular Diagnostics

Introduction: Diagnostic Precision in a Time-Critical World

In the clinical environment, early detection and targeted treatment are critical, especially in time-sensitive cases like suspected sepsis, where every hour without appropriate antimicrobial therapy can significantly increase the risk of mortality or morbidity[1].

Yet, for decades, clinicians have had to rely primarily on blood cultures and phenotypic methods to guide diagnosis — despite their known limitations, including prolonged time to results and reduced sensitivity in patients with prior antibiotic exposure or low-level bacteremia.

The InfectID™-BSI panel addresses many of these challenges by providing early clinical intelligence for the top 95% of known sepsis-causing pathogens. It can also detect certain fastidious organisms and those potentially suppressed by earlier antimicrobial therapy, helping to fill critical gaps left by conventional culture.

As the demand grows for faster, more accurate, and actionable diagnostic insights, molecular diagnostics continues to emerge as a transformative tool in the hands of clinicians.

This guide explores the fundamentals of molecular diagnostics, how these technologies are currently applied in clinical practice, and how ongoing innovations continue to advance the field of clinical microbiology and infectious disease management.

What is Molecular Diagnostics?

Molecular diagnostics refers to a category of testing methods that are used to help identify a disease or the risk of developing a disease by studying molecules, such as DNA, RNA, and proteins, in a tissue or body fluid sample.[2]

Molecular diagnostics can detect and analyze genetic material from pathogens to identify infectious diseases in clinical scenarios where there is a low level of organism or possibly a hard to grow microorganism. Instead of growing organisms in culture, molecular assays target specific nucleic acid sequences that are unique to bacteria, viruses, fungi, or parasites.

This shift from growth-based to molecular-based identification enables rapid and highly specific detection — particularly when pathogens are present in low concentrations or are difficult to culture.

Core Technologies in Molecular Diagnostics:

  • Polymerase Chain Reaction (PCR): A foundational technique that uses thermal cycling (repeated heating and cooling) to amplify tiny amounts of DNA to detectable levels.
  • Real-time Quantitative PCR (qPCR): A type of PCR that monitors DNA or RNA amplification as it occurs, using fluorescent signals detected during each thermal cycle. This provides both qualitative (presence/absence) and quantitative (amount) information without the need for post-PCR processing.
  • Multiplex PCR: Detects multiple pathogens in a single test—particularly useful in syndromic panels for bloodstream or respiratory infections.
  • Microarrays: Enable the simultaneous analysis of thousands of DNA sequences, useful for detecting gene expression patterns or a wide array of pathogens in parallel.
  • Next-Generation Sequencing (NGS): Offers deep genomic profiling, capable of identifying novel or unexpected pathogens.
  • Isothermal amplification: Rapid and simplified techniques (e.g., LAMP) that don’t require thermal cycling, useful for point-of-care settings.

Why Molecular Diagnostics Matters in Clinical Care

Speed to Results

In contrast to traditional blood cultures, molecular assays being developed today typically return results in under 6 hours, allowing clinicians to act sooner. This speed matters. In sepsis, each hour of delayed appropriate antibiotic therapy has been associated with a measurable increase in mortality[1]. Rapid pathogen identification can help streamline treatment decisions, reduce empirical broad-spectrum antibiotic use, and improve outcomes.[3]

Accuracy and Sensitivity

Molecular tests are highly sensitive and specific[4]. They can also detect DNA (or RNA) from pathogens that are slow-growing, fastidious, or rendered non-viable by prior antibiotic treatment. This improves diagnostic yield in patients who might otherwise have negative cultures despite clinical signs of infection.

Broader Pathogen Coverage

Many molecular platforms use multiplex panels to test for dozens of pathogens in a single test. This is particularly beneficial in syndromic testing—where symptoms could be due to a range of possible organisms—and in critically ill patients where time is of the essence.

Antimicrobial Stewardship

Faster, more precise identification supports targeted antimicrobial therapy[5][6]. Clinicians can de-escalate treatment when appropriate, helping to reduce resistance pressure and improve stewardship practices or even escalate when coverage is not broad enough after the first dose.

Applications in Sepsis and Infectious Disease

Sepsis, a life-threatening complication of infection, is a leading cause of hospital mortality and morbidity worldwide[7]. The condition often progresses rapidly, and delayed identification of the causative organism is a significant barrier to optimal treatment.

Molecular diagnostics can:

  • Detect bloodstream pathogens more quickly than blood culture[8]
  • Identify (quicker with more sensitivity) mixed infections or unexpected pathogens[9]
  • Support early, appropriate antibiotic selection[10]
  • Reduce unnecessary use of broad-spectrum antimicrobials[11]

Beyond sepsis, molecular diagnostics are used in diagnosing:

  • Respiratory infections (e.g., influenza, SARS-CoV-2)
  • Gastrointestinal pathogens
  • Meningitis/encephalitis syndromes
  • Hospital-acquired infections
  • Antimicrobial resistance genes (e.g., MRSA, ESBL, carbapenemases)

Clinical Considerations

While the benefits are compelling, molecular diagnostics in sepsis today are not a replacement for culture-based methods. Traditional microbiology remains essential for antimicrobial susceptibility testing for bacterial and fungal species.

To ensure optimal use of molecular diagnostics, clinicians and laboratories should consider:

  • Test selection: Choosing between syndromic panels and targeted assays depends on the clinical scenario. Broad panels may be valuable in critically ill or immunocompromised patients where the differential diagnosis is wide, while targeted tests are more appropriate when a specific pathogen is suspected.
  • Clinical context: Molecular tests can detect DNA or RNA from live or dead organisms, including colonizers. This means positive results do not always indicate active infection. Clinical teams must interpret results considering the patient’s signs and symptoms, immune status, and site of specimen collection. For instance, a positive PCR for a respiratory pathogen in an asymptomatic patient may reflect colonization rather than infection.
  • Workflow integration: To maximize impact, results from rapid molecular diagnostics should be integrated into antimicrobial stewardship and clinical decision-making workflows. Timely communication of results, often within a few hours, can influence antimicrobial choices, de-escalation, or escalation decisions — but only if teams are prepared to act on the data.

The Future of Molecular Diagnostics for Infectious Disease

Advances in automation, miniaturization, data analytics, quantum computing and artificial intelligence continue to expand the reach of molecular diagnostics. New platforms are emerging with:

  • Faster run times
  • Expanded pathogen panels
  • Integrated antimicrobial resistance gene detection
  • Point-of-care or nearer to patient capabilities

In the coming years, we can expect broader adoption across emergency departments, ICUs, and even outpatient settings — bringing rapid, actionable insights closer to the bedside.

InfectID™-BSI is designed to meet an evolving need in the sepsis arena — bringing rapid, accurate pathogen identification directly to clinicians managing bloodstream infections. By combining broad pathogen detection with the speed of molecular testing, InfectID™-BSI supports earlier, more informed decision-making in critical care settings. Its streamlined workflow and actionable results aim to integrate seamlessly into existing diagnostic pathways, helping healthcare teams respond faster and with greater precision in cases of suspected sepsis and other serious infections.

Microbio’s Application of Molecular Diagnostics

Molecular diagnostics has become an established part of infectious disease management over the past decade, offering rapid, accurate, and comprehensive pathogen detection. In time-critical conditions like sepsis, timely access to this information can support early, targeted therapy and guide antimicrobial decisions — ultimately improving patient outcomes and supporting antimicrobial stewardship.

Whilst there is no singular, globally accepted generic sepsis pathway integrating molecular testing, general principles for ordering can be applied:

  • Undifferentiated patients in the emergency department: Risk assessment indicates high or moderate risk of sepsis, order qPCR as an adjunct to blood cultures.
  • Critical care: Patients usually exposed to prior antibiotics — frequency of qPCR testing contingent on clinical context.
  • Neonates: Neonatologists try to limit intravenous antimicrobial therapy to 2 days and thus require clinical intelligence early — qPCR could be ordered more frequently due to low blood volume required compared to blood culture
  • Immunocompromised or multiple comorbidities: This cohort of patients often have polymicrobial infections or already on antimicrobial therapy — frequency of qPCR ordering contingent on clinical context.

InfectID™-BSI is a supplement tool for traditional methods of sepsis management. In the emergency department setting, all patients have a sepsis risk assessment. The patients meeting the criteria for high or moderate risk of sepsis require rapid qPCR to provide early identification of the pathogen’s genus and species to allow more target antimicrobial therapy.

In the inpatient setting, any patient not responding to current therapy and meets the criteria for possible infection or sepsis should have InfectID™-BSI testing. Any immunocompromised patient should be considered for InfectID™-BSI testing.

As accessibility and integration improve, molecular diagnostics will continue to enhance precision in infectious disease care.

References
  1. Kumar A, Roberts D, Wood KE, Light B, Parrillo JE, Sharma S, Suppes R, Feinstein D, Zanotti S, Taiberg L, Gurka D, Kumar A, Cheang M. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med. 2006 Jun;34(6):1589-96. ​doi: 10.1097/01.CCM.0000217961.75225.E9. PMID: 16625125.​[↩][↩]
  2. https://www.cancer.gov/publications/dictionaries/cancer-terms/def/molecular-diagnostics[↩]
  3. D’Onofrio V, Salimans L, Bedenic B, Cartuyvels R, Barišic I, Gyssens IC. The Clinical Impact of Rapid Molecular Microbiological Diagnostics for Pathogen and Resistance Gene Identification in Patients With Sepsis: A Systematic Review. Open Forum Infect Dis. 2020;7(10):ofaa352. Published 2020 Aug 13. doi:10.1093/ofid/ofaa352[↩]
  4. Yang S, Lin S, Khalil A, et al. Quantitative PCR assay using sputum samples for rapid diagnosis of pneumococcal pneumonia in adult emergency department patients. J Clin Microbiol. 2005;43:3221–6. doi: 10.1128/JCM.43.7.3221-3226.2005.[↩]
  5. https://www.ncbi.nlm.nih.gov/books/NBK572068/

    [↩]

  6. Moody J, Cosgrove SE, Olmsted R, et al. Antimicrobial stewardship: a collaborative partnership between infection preventionists and health care epidemiologists. Am J Infect Control. 2012;40(2):94-95. doi:10.1016/j.ajic.2012.01.001[↩]
  7. World Health Organization. Sepsis. https://www.who.int/news-room/fact-sheets/detail/sepsis. Accessed June 2025.[↩]
  8. Fabre V, Sharara SL, Salinas AB, Carroll KC, Wang MC, Cosgrove SE. Molecular diagnostics in bloodstream infections: rapid identification and antimicrobial stewardship. Lancet Infect Dis. 2024;24(5):521-531. doi:10.1016/S2589-5370(24)00607-2[↩]
  9. Badran S, Chen M, Coia JE. Multiplex Droplet Digital Polymerase Chain Reaction Assay for Rapid Molecular Detection of Pathogens in Patients With Sepsis: Protocol for an Assay Development Study. JMIR Res Protoc. 2021 Dec 13;10(12):e33746. doi: 10.2196/33746[↩]
  10. Timbrook TT, Morton JB, McConeghy KW, Caffrey AR, Mylonakis E, LaPlante KL. The Effect of Molecular Rapid Diagnostic Testing on Clinical Outcomes in Bloodstream Infections: A Systematic Review and Meta-analysis. Clin Infect Dis. 2017;64(1):15-23. doi:10.1093/cid/ciw649[↩]
  11. Banerjee R, Teng CB, Cunningham SA, et al. Randomized Trial of Rapid Multiplex Polymerase Chain Reaction-Based Blood Culture Identification and Susceptibility Testing. Clin Infect Dis. 2015;61(7):1071-1080. doi:10.1093/cid/civ447[↩]